Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Muhammad Azrif Bin Ahmad Annuar"'
Publikováno v:
Clinical Breast Cancer. 18:e1173-e1179
Nonhematologic adverse events (AEs) of docetaxel constitute an extra burden in the treatment of cancer patients and necessitate either a dose reduction or an outright switch of docetaxel for other regimens. These AEs are frequently associated with ge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f355c2d4ca916a2f6983208d993489e7
https://doi.org/10.1016/j.clbc.2018.04.018
https://doi.org/10.1016/j.clbc.2018.04.018
Publikováno v:
Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals. 23(2)
Rash and oral mucositis are major non-haematological adverse events (AEs) of docetaxel, in addition to fatigue, nausea, vomiting and diarrhoea, which restrict the use of the drug in cancer therapy. Alpha-1-acid glycoprotein (AAG) is an acute phase re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87d0b8e72485e737b9473768d48e3dab
https://pubmed.ncbi.nlm.nih.gov/28554261
https://pubmed.ncbi.nlm.nih.gov/28554261
Autor:
Ahmad Zailani Hatta Mohd Dali, A. Rahman A. Jamal, Ilambarthi Lokamani, Muhammad Azrif Bin Ahmad Annuar, Siti Aishah Md Ali, Mee Lee Looi
Publikováno v:
Pathology oncology research : POR. 20(1)
This study aimed to identify candidate proteins which may serve as potential biological markers for cervical cancer using 2D-DIGE. Serum samples of controls, patients with cervical intraepithelial neoplasia grade 3 (CIN 3), squamous cell carcinoma of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4ae98fe31879ac58fb2abeb03419bd1
https://pubmed.ncbi.nlm.nih.gov/23925487
https://pubmed.ncbi.nlm.nih.gov/23925487
Autor:
Rakesh Naidu, Murali Munisamy, Muhammad Azrif Bin Ahmad Annuar, Johnson Stanslas, Gwo Fuang Ho, Rafid Salim Jabir
Publikováno v:
Pharmacogenomics. 13(16)
Interindividual variability in drug response and the emergence of adverse drug effects are the main causes of treatment failure in cancer therapy. Functional membrane drug transporters play important roles in altering pharmacokinetic profile, resista
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6759f075ec79258a2d971f85d77ff3c
https://pubmed.ncbi.nlm.nih.gov/23215890
https://pubmed.ncbi.nlm.nih.gov/23215890
Publikováno v:
Molecular Cancer Therapeutics. 12:A210-A210
Docetaxel is an antitubulin chemotherapeutic agent approved for the treatment of breast, lung, ovarian and non-hormonal dependent prostate cancers. However, the success of this drug is limited by adverse effects (AEs), the severity of which ranged fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0aac466a6944b4ad7476bc1d36e4131
https://doi.org/10.1158/1535-7163.targ-13-a210
https://doi.org/10.1158/1535-7163.targ-13-a210